Hetero Labs Gets CDSCO Panel Nod To Study Antibiotic Tebipenem Pivoxil Dispersible Tablet
New Delhi: Stating that the decision to waive off the clinical trial will be taken after a review of the Bioequivalence study report, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the drug major Hetero Labs to conduct the bioequivalence (BE) study of the Tebipenem Pivoxil Dispersible tablets 50mg.
This came after the firm presented the proposal for a grant of permission to conduct a bioequivalence study and justification for Phase III clinical trial waiver with the drug Tebipenem Pivoxil Dispersible tablets 50mg.
Tebipenem Pivoxil is an orally available pivaloyloxymethyl ester prodrug of tebipenem, a broad-spectrum 1-beta-methylcarbapenem antibiotic with a 1-(1,3-thiazolin-2-yl) azetidin-3-ylthio group at the C-2 position. After oral administration of tebipenem pivoxil, the ester bond is cleaved, releasing active tebipenem.
Tebipenem is a broad-spectrum orally-administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics. Tebipenem is formulated as the ester tebipenem pivoxil due to the better absorption and improved bioavailability of this form.
Tebipenem acts by binding to penicillin-binding proteins, inhibiting the synthesis of the bacterial cell wall. This results in the weakening of peptidoglycan, leading to lysis of bacterial cells
At the recent SEC meeting for Antimicrobial and Antiviral held on 28th June 2023, the expert panel reviewed the proposal presented by Hetero Labs for a grant of permission to conduct a bioequivalence study and justification for Phase III clinical trial waiver with the drug Tebipenem Pivoxil Dispersible tablets 50mg.
After detailed deliberation, the committee recommended that the firm may conduct BE study as per the protocol presented and submit the BE study results.
Furthermore, the expert panel added that the decision to waive the clinical trial will be taken after a review of Bioequivalence the study report, subject to regulatory compliance as per CDSCO guidelines.
Also Read: Akums Pharma Gets CDSCO Panel Nod To Manufacture, Market Tamsulosin HCL, Tadalafil FDC Tablet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.